Evidence map›Paper›PMID 41777880›Full record

ArticleFrontiers in immunology2026

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report.

Torsten Schroeder, Guranda Chitadze, Justina Dargvainiene, Tjark Martens, Niklas Gebauer, Julia Frimmel, Monika Brüggemann, Thomas Valerius, Natalie Schub, Claudia D Baldus and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Torsten SchroederDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Guranda ChitadzeDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Justina DargvainieneInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Tjark MartensDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Niklas GebauerDepartment of Haematology and Oncology, University Hospital Schleswig-Holstein Lübeck, University of Lübeck, Lübeck, Germany.
Julia FrimmelDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Monika BrüggemannDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Thomas ValeriusDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Natalie SchubDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Claudia D BaldusDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Christiane PottDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Frank LeypoldtInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Klarissa StürnerDepartment of Neurology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.
Friedrich StölzelDepartment of Medicine II, Department of Haematology and Oncology, University Hospital Schleswig-Holstein Kiel, Kiel University, Kiel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a 63-year-old male patient with diffuse large B-cell lymphoma (DLBCL) who developed delayed-onset neurotoxicity on day +22 following CD19-directed CAR T-cell therapy with axicabtagene ciloleucel (axi-cel), after an initial episode of CRS and ICANS. The underlying disease had relapsed with secondary central nervous system (CNS) involvement, highlighting a high-risk setting for neurotoxicity. Unlike classical ICANS, the syndrome featured progressive gait ataxia and hypokinetic movement disturbances-clinical hallmarks of so-called movement and neurocognitive treatment-emergent adverse events (MNTs), a syndrome often referred to as parkinsonism due to characteristic features such as bradykinesia, rigidity, tremor, and cognitive slowing. To date, such MNTs have only been reported in patients receiving BCMA-targeted CAR T-cell products, primarily for multiple myeloma. Our report is, to the best of our knowledge, the first documented case of an MNT-like syndrome following CD19-directed CAR T-cell therapy. The patient's symptoms evolved subacutely, in the absence of radiographic progression, infection, or lymphoma relapse. Immunophenotyping revealed activated effector-memory CD8

Indexed as

Antigens, CD19Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseNeurotoxicity SyndromesBiological ProductsHumansMaleMiddle AgedReceptors, Chimeric AntigenAntigens, CD19axicabtagene ciloleucelBiological ProductsReceptors, Chimeric AntigenCAR T-cell therapycase reportCD19ICANSMNTSneurotoxicity

Identifiers

PMID41777880
PMCPMC12950781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.